Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback

Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback Summary Oramed remains viable after its flagship product failed FDA trials three years ago. Management identified a responsive patient subset-elderly with low BMI and high baseline HbA1c-prompting a new 60-patient trial. Positive results from ORMP's Chinese partner reinforce the potential for this narrower patient group. Validating the Protein Oral Delivery Platform in this subset could unlock broader applications beyond insulin. Analyst’s Disclosure: I/we have a beneficial long position in the shares of ORMP either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Preview: ~215 words